VERTEX PHARMACEUTICALS INC / MA Deferred Tax Assets, Tax Credit Carryforwards
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Deferred Tax Assets, Tax Credit Carryforwards of $355.80 million as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxCreditCarryforwards · last filed 2026-02-13
- 2025-12-31: Deferred Tax Assets, Tax Credit Carryforwards $355.80M.
- 2024-12-31: Deferred Tax Assets, Tax Credit Carryforwards $298.30M.
- 2023-12-31: Deferred Tax Assets, Tax Credit Carryforwards $261.00M.
- 2022-12-31: Deferred Tax Assets, Tax Credit Carryforwards $223.00M.
| Period end | Deferred Tax Assets, Tax Credit Carryforwards | Deferred Tax Assets, Tax Credit Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $355.80M 10-K · filed 2026-02-13 | |
| 2024-12-31 | $298.30M 10-K · filed 2026-02-13 | |
| 2023-12-31 | $261.00M 10-K · filed 2025-02-13 | |
| 2022-12-31 | $223.00M 10-K · filed 2024-02-15 | |
| 2021-12-31 | $202.40M 10-K · filed 2023-02-10 | |
| 2020-12-31 | $406.10M 10-K · filed 2022-02-09 | $406.12M 10-K · filed 2021-02-11 |
| 2019-12-31 | $549.54M 10-K · filed 2021-02-11 | |
| 2018-12-31 | $487.63M 10-K · filed 2020-02-13 | |
| 2017-12-31 | $440.43M 10-K · filed 2019-02-13 | |
| 2016-12-31 | $367.40M 10-K · filed 2018-02-15 | |
| 2015-12-31 | $315.54M 10-K · filed 2017-02-23 | |
| 2014-12-31 | $265.34M 10-K · filed 2016-02-16 | |
| 2013-12-31 | $180.38M 10-K · filed 2015-02-13 | |
| 2012-12-31 | $147.07M 10-K · filed 2014-02-11 | |
| 2011-12-31 | $167.76M 10-K · filed 2013-03-01 | |
| 2010-12-31 | $112.47M 10-K · filed 2012-02-22 | |
| 2009-12-31 | $83.56M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |